Growth Metrics

LeonaBio (LONA) Convertible Debt (2019)

LeonaBio (LONA) reported Convertible Debt of $1.6 million for Q4 2019.

LeonaBio (LONA) has 1 years of Convertible Debt data on file, last reported at $1.6 million in Q4 2019.

  • Quarterly Convertible Debt changed N/A year-over-year to $1.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $1.6 million (changed N/A YoY) and the FY2019 annual result came in at $1.6 million, changed N/A from the prior year.
  • Convertible Debt held at $1.6 million in Q4 2019 per LONA's latest filing.
  • Across five years, Convertible Debt topped out at $1.6 million in Q4 2019 and bottomed at $1.6 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 LeonaBio 181.52 Mn 113.84 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 1.55 Mn